p38 MAPK associated with stereoselective priming by grepafloxacin on O 2- production in neutrophils

Free Radical Biology and Medicine

Volumn 36, Issue 10, 2004, Pages 1259-1269

  Niwa, Masayuki ^a,d   Hotta, Koichi ^a   Kanamori, Yutaka ^a   Kumada, Masako ^a   Hirota, Masao ^c   Kozawa, Osamu ^a   Fujimoto, Sadaki ^b  

^a GIFU UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c Tokushima Research Institute   (Japan)

^d GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Binding site; c Jun N terminal kinase; Fluoroquinolone antimicrobial agents; Free radicals; GCSF; Granulocyte colony stimulating factor; Grepafloxacin; Human neutrophils; JNK; MAPK; Mitogen activated protein kinase; p38 MAPK; p47 phox; Stereoisomer; Superoxide

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GREPAFLOXACIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXYGEN; PROTEIN P44; PROTEIN P47; PROTEIN P67; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CHROMOSOME TRANSLOCATION; CONCENTRATION RESPONSE; DRUG POTENCY; ENANTIOMER; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; NEUTROPHIL; PRIORITY JOURNAL; STEREOCHEMISTRY;

CELL MEMBRANE; ENZYME INHIBITORS; FLUOROQUINOLONES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NADPH OXIDASE; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN TRANSPORT; RESPIRATORY BURST; STEREOISOMERISM; SUPEROXIDES;

EID: 1942488291     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.02.066     Document Type: Article

References (50)

1. Child J., Andrews J.M., Wise R. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob. Agents Chemother. 39:1995;513-515.
2. Kozawa O., Uematsu T., Matsuno H., Niwa M., Nagashima S., Kanamaru M. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrob. Agents Chemother. 40:1996;2824-2828.
3. Tanimura M., Kobuchi H., Utsumi T., Yoshioka T., Kataoka S., Fujita Y., Utsumi K. Neutrophil priming by granulocyte colony stimulating factor and its modulation by protein kinase inhibitors. Biochem. Pharmacol. 44:1992;1045-1052.
4. Fu K.P., Hilliard J., Isaacson D., Tobia A.J., Rosenthale M.E., McGuire J.L. In-vivo evaluation of ofloxacin in Salmonella typhimurium infection in mice. J. Antimicrob. Chemother. 25:1990;263-268.
5. Havlichek D., Saravolatz L., Pohlod D. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob. Agents Chemother. 31:1987;1529-1534.
6. Nielsen S.L., Obel N., Storgaard M., Andersen P.L. The effect of quinolones on the intracellular killing of Staphylococcus aureus in neutrophil granulocytes. J. Antimicrob. Chemother. 39:1997;617-622.
7. Wakebe H., Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob. Agents Chemother. 36:1992;2185-2191.
8. Imada T., Miyazaki S., Nishida M., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob. Agents Chemother. 36:1992;573-579.
9. Uematsu T., Nakashima M. Pharmacokinetic aspects of newer quinolone. Progress in drug research. Vol. 38:1992;39-56 Birkhauser Verlag, Basel.
10. Cook P., Andrews J.M., Wise R., Honeybourne D., Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35:1995;317-326.
11. Niwa M., Hotta K., Kanamori Y., Matsuno H., Kozawa O., Hirota M., Uematsu T. Differential uptake of grepafloxacin by human circulating blood neutrophils and those exudated into tissues. Eur. J. Pharmacol. 428:2001;121-126.
12. Sasabe H., Kato Y., Terasaki T., Tsuji A., Sugiyama Y. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. Biopharm. Drug Dispos. 20:1999;151-158.
13. Taira K., Koga H., Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 37:1993;1877-1881.
14. Hotta K., Niwa M., Hirota M., Kanamori Y., Matsuno H., Kozawa O., Otsuka T., Matsui N., Uematsu T. Regulation of fluoroquinolone uptake by human neutrophils: involvement of mitogen-activated protein kinase. J. Antimicrob. Chemother. 49:2002;953-959.
15. Cross A.S., Lowell G.H. Stimulation of polymorphonuclear leukocyte bactericidal activity by supernatants of activated human mononuclear cells. Infect. Immun. 22:1978;502-507.
16. Cross A.S., Lowell G.H., Palmblad J.C., Sadoff J.C., Young L., Berger M. Mechanism of priming of human neutrophils by a soluble lymphoblastoid cell factor. J. Immunol. 135:1985;2074-2083.
17. Vadas M.A., Nicola N., Lopez A.F., Metcalf D., Johnson G., Pereira A. Mononuclear cell-mediated enhancement of granulocyte function in man. J. Immunol. 133:1984;202-207.
18. Kitagawa S., You A., Souza L.M., Saito M., Miura Y., Takaku F. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide. Biochem. Biophys. Res. Commun. 144:1987;1143-1146.
19. Klebanoff S.J., Vadas M.A., Harlan J.M., Sparks L.H., Gamble J.R., Agosti J.M., Waltersdorph A.M. Stimulation of neutrophils by tumor necrosis factor. J. Immunol. 136:1986;4220-4225.
20. Niwa M., Yousif A.E., Kohno K., Kanamori Y., Matsuno M., Abe A., Uematsu T. The loss of recombinant human granulocyte colony-stimulating factor and recombinant human TNF-alpha priming effects on the superoxide-generating response in exudated neutrophils is associated with a decrease in their receptor affinities. J. Immunol. 157:1996;4147-4153.
21. Sullivan R., Griffin J.D., Simons E.R., Schafer A.I., Meshulam T., Fredette J.P., Maas A.K., Gadenne A.S., Leavitt J.I., Melnick D.A. Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J. Immunol. 139:1987;3422-3430.
22. Aoki M., Ono Y., Kunii O., Goldstein E. Effect of newer quinolones on the extra- and intra-cellular chemiluminescence response of human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 34:1994;383-390.
23. Kubo S., Matsumoto T., Takahashi K., Haraoka M., Tanaka M., Sakumoto M., Sakamoto Y., Kumazawa J. Enhanced chemiluminescence response of polymorphonuclear leukocytes by new quinolone antimicrobials. Chemotherapy. 40:1994;333-336.
24. Matsumoto T., Takahashi K., Nagafuji T., Kubo S., Kumazawa J. Effect of inhibitors of protein kinase C on enhanced superoxide production of human leucocytes by ofloxacin and fleroxacin. Drugs. 49(Suppl. 2):1995;286-288.
25. Matsumoto T., Takahashi K., Nagafuji T., Kubo S., Sakumoto M., Mochida O., Sakamoto Y., Mizunoe Y., Kumazawa J. Fleroxacin enhancement of superoxide production by polymorphonuclear leukocytes: the role of protein kinases. Chemotherapy. 42:1996;280-285.
26. Niwa M., Hotta K., Kanamori Y., Hatakeyama D., Hirade K., Katayama M., Hara A., Mori H., Ito H., Kato K., Matsuno H., Uematsu T., Kozawa O. Involvement of p38 mitogen-activated protein kinase in heat shock protein 27 induction in human neutrophils. Eur. J. Pharmacol. 466:2003;245-253.
27. Sasabe H., Kato Y., Tsuji A., Sugiyama Y. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. J. Pharmacol. Exp. Ther. 284:1998;661-668.
28. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 97:1968;77-89.
29. Niwa M., Kohno K., Al-Essa L.Y., Kobayashi M., Nozaki M., Tsurumi K. Ibudilast, an anti-allergic and cerebral vasodilator, modulates superoxide production in human neutrophils. Life Sci. 56:1995;107-115.
30. Babior B.M., Kipnes R.S., Curnutte J.T. Biological defense mechanisms: the production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52:1973;741-744.
31. Al-Essa L.Y., Niwa M., Kohno K., Nozaki M., Tsurumi K. Heterogeneity of circulating and exudated polymorphonuclear leukocytes in superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents: investigation of the underlying mechanism. Biochem. Pharmacol. 49:1995;315-322.
32. -. Anal. Biochem. 159:1986;363-369.
33. Suzuki N., Suetsuna K., Mashiko S., Yoda B., Nomoto T., Toya Y., Inaba H., Goto T. Reaction rates for the chemiluminescence of Cypridina luciferin analogues with superoxide: a quenching experiment with superoxide dismutase. Agric. Biol. Chem. 55:1991;157-160.
34. Kawakami N., Takemasa H., Yamaguchi T., Hayakawa T., Shimohama S., Fujimoto S. Indication of a protein kinase C-independent pathway for NADPH oxidase activation in human neutrophils. Arch. Biochem. Biophys. 349:1998;89-94.
35. Fujimoto S., Smith R.M., Curnutte J.T., Babior B.M. Evidence that activation of the respiratory burst oxidase in a cell-free system from human neutrophils is accomplished in part through an alteration of the oxidase-related 67-kDa cytosolic protein. J. Biol. Chem. 264:1989;21629-21632.
36. Kawakami N., Shimohama S., Hayakawa T., Sumida Y., Fujimoto S. Tyrosine phosphorylation and translocation of phospholipase C-gamma 2 in polymorphonuclear leukocytes treated with pervanadate. Biochim. Biophys. Acta. 1314:1996;167-174.
37. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
38. Williams L.T., Snyderman R., Pike M.C., Lefkowitz R.J. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc. Natl. Acad. Sci. USA. 74:1977;1204-1208.
39. Koo C., Lefkowitz R.J., Snyderman R. The oligopeptide chemotactic factor receptor on human polymorphonuclear leukocyte membranes exists in two affinity states. Biochem. Biophys. Res. Commun. 106:1982;442-449.
40. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., Lee J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:1995;229-233.
41. Kummer J.L., Rao P.K., Heidenreich K.A. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem. 272:1997;20490-20494.
42. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:1995;27489-27494.
43. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA. 98:2001;13681-13686.
44. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., Young P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746.
45. Niwa M., Kanamori Y., Hotta K., Matsuno H., Kozawa O., Fujimoto S., Uematsu T. Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism. J. Antimicrob. Chemother. 50:2002;469-478.
46. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79:1999;143-180.
47. Zhong B., Jiang K., Gilvary D.L., Epling-Burnette P.K., Ritchey C., Liu J., Jackson R.J., Hong-Geller E., Wei S. Human neutrophils utilize a Rac/Cdc42-dependent MAPK pathway to direct intracellular granule mobilization towards ingested microbial pathogens. Blood. 101:2003;3240-3248.
48. Nick J.A., Young S.K., Arndt P.G., Lieber J.G., Suratt B.T., Poch K.R., Avdi N.J., Malcolm K.C., Taube C., Henson P.M., Worthen G.S. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J. Immunol. 169:2002;5260-5269.
49. Mitscher L.A., Sharma P.N., Chu D.T., Shen L.L., Pernet A.G. Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro- 7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). J. Med. Chem. 30:1987;2283-2286.
50. Gordon K.A., Sader H.S., Jones R.N. Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States. Diagn. Microbiol. Infect. Dis. 47:2003;377-383.